Epigenomic Priming as an Immunotherapy Enhancer in Ovarian Cancer

Abstract

New immunologic approaches targeting immune checkpoint pathways, such as the programmed cell death protein-1 (PD-1) are under clinical development for solid tumors, including ovarian cancer (OC). Anti-PD1 strategies prevent T-cell exhaustion, augmenting immune anti-tumor responses. The focus of this application is to develop a combination regimen that enhances the activity of PD1-targeted immunotherapy in a clinical trial designed for women with recurrent ovarian cancer. We speculate that an important mechanism of immune evasion in OC is represented by epigenetic silencing of tumor antigens. One of the mechanisms of transcriptional repression of tumor antigens.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
May 01, 2020
Accession Number
AD1130755

Entities

People

  • Bin Zhang
  • Daniela E. Matei
  • Hao Huang
  • Horacio Cardenas
  • Siqi Chen

Organizations

  • Northwestern University

Tags

DTIC Thesaurus Topics

  • Abstracts
  • Breast Cancer
  • Cancer
  • Cell Physiological Processes
  • Cells
  • Clinical Trials
  • Combination Therapy
  • Department Of Defense
  • Immunity
  • Immunotherapy
  • Inhibition
  • Lymphocytes
  • Medical Personnel
  • Neoplasms
  • Nucleic Acids
  • Oncology
  • Ovarian Cancer
  • Patent Applications
  • Programmed Cell Death
  • Prostate Cancer
  • Resistance
  • Stem Cells
  • Students
  • Therapy
  • Vaccines

Fields of Study

  • Biology

Readers

  • Oncology

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech